Last reviewed · How we verify
Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral®(Cyclosporine) and Standard Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral®(Cyclosporine) and Reduced Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients (MyLowCsA)
To demonstrate that cyclosporine-sparing immunosuppressions with the standard dose of Enteric-Coated Mycophenolate Sodium would preserve renal graft function after transplantation without an increase of incidences of adverse events, such as biopsy confirmed acute rejection, local or systemic infections, and bone marrow suppression.
Details
| Lead sponsor | Samsung Medical Center |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 140 |
| Start date | 2011-06 |
| Completion | 2013-08 |
Conditions
- Chronic Renal Disease
Interventions
- Standard Dose of Myfortic and Reduced Dose of Myfortic
- Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
- Basiliximab injected both control group and experimental group
Primary outcomes
- eGFR (abbreviated MDRD equation) — 6 months after transplantation
Primary objective: To compare the renal function with eGFR (abbreviated MDRD equation) 6 months after transplantation